The effectiveness of the long-term administration of therapeutic agents used for idiopathic short stature (ISS), such as recombinant human growth hormone (rhGH), aromatase inhibitors, metformin, and insulin-like growth factor-1 (IGF-1), remains a topic of controversy. The gene discussed is GH1; the disease is SHOX-related short stature.